VTRSHealthcare · Drug Manufacturers - Specialty & GenericThe 10 Wall Street analysts covering Viatris, Inc. hold a median 12-month price target of $18 — +2.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 1 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Viatris, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (96): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Revisions (60): Analysts have, on balance, been cutting their forecasts.
Size (10): Larger than most of the companies we track — more scrutinised, less often mispriced.
The rank is the raw material. Whether the rules would actually own Viatris, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on VTRS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +2.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 May 2026 | Barclays | Maintains | Overweight | $17 → $22 |
| 8 May 2026 | JP Morgan | Maintains | Neutral | — |
| 8 May 2026 | Truist Securities | Maintains | Buy | — |
| 24 Mar 2026 | Barclays | Maintains | Overweight | — |
| 28 Jan 2026 | Piper Sandler | Maintains | Neutral | — |
| 16 Jan 2026 | Argus Research | Upgrade | Buy | — |
| 9 Dec 2025 | Barclays | Initiates | Overweight | — |
| 15 Oct 2025 | Truist Securities | Initiates | Buy | — |
| 6 June 2025 | Goldman Sachs | Initiates | Neutral | — |
| 7 Mar 2025 | Jefferies | Maintains | Buy | — |
| 5 Mar 2025 | Piper Sandler | Reiterates | Neutral | — |
| 28 Feb 2025 | B of A Securities | Maintains | Underperform | — |
| 28 Feb 2025 | Barclays | Maintains | Underweight | — |
| 6 Dec 2024 | Piper Sandler | Reiterates | Neutral | — |
| 8 Nov 2024 | Barclays | Maintains | Underweight | — |
| 19 July 2024 | Jefferies | Reinstates | Buy | $15 |
| 28 Mar 2024 | Piper Sandler | Reiterates | Neutral | — |
| 22 Nov 2023 | Piper Sandler | Maintains | Neutral | — |
| 23 Oct 2023 | B of A Securities | Downgrade | Underperform | — |
| 23 June 2023 | Barclays | Downgrade | Underweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 3% of US stocks
Cheaper than 62% of US stocks
Cheaper than 59% of US stocks
Cheaper than 46% of US stocks
Higher than 50% of US stocks
Higher than 48% of US stocks
Higher than 41% of US stocks
Higher than 61% of US stocks
Higher than 27% of US stocks
Higher than 42% of US stocks
Higher than 61% of US stocks
Higher than 60% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VTRS appears on the weeks it earns a place.
Zacks Investment Research published a preview of Viatris's Q2 earnings report, noting the company lacks the right combination of key ingredients for a likely earnings beat.
Why it matters — VTRS watchers would care because the preview suggests the upcoming quarterly earnings report may be weaker than expected.
Viatris announced that the U.S. FDA has approved Gwyn Lo, a once-weekly combined hormonal contraceptive patch with low-dose estrogen.
Why it matters — This approval marks a milestone in Viatris' efforts to advance its women's health portfolio and adds a new product to its commercial offerings.
The 10 Wall Street analysts covering Viatris, Inc. have a median 12-month price target of $18, with estimates ranging from $12 to $23. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 10 analysts covering Viatris, Inc., 5 rate it a Buy, 4 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Viatris, Inc. 96 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Viatris, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (96 of 100).
No one can know that. What the data says: the median 12-month target from 10 analysts implies +2.1% from the last close, and Ticker Nerd's factor model ranks Viatris, Inc. 96 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Viatris, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VTRS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $23 over the next 12 months.
Viatris, Inc. returned +108.1% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Viatris Inc. is a global healthcare and pharmaceutical company headquartered in Canonsburg, Pennsylvania, United States.
The most recent item we track (Zacks Investment Research, 30 July 2026): "Viatris (VTRS) Q2 Earnings Preview: What's in the Cards?". Zacks Investment Research published a preview of Viatris's Q2 earnings report, noting the company lacks the right combination of key ingredients for a likely earnings beat.
Viatris Inc. is a global healthcare and pharmaceutical company headquartered in Canonsburg, Pennsylvania, United States. It focuses on expanding access to a broad range of trusted, quality medications across both noncommunicable and infectious diseases, serving patients in developed and emerging markets worldwide. Viatris markets a diversified portfolio that includes branded and generic prescription drugs, complex medicines, biosimilars, and over-the-counter products, covering more than ten major therapeutic areas such as cardiovascular, oncology, infectious disease, respiratory, diabetes, and women’s health. The company operates through four primary geographic segments: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets, reflecting its broad international footprint. Viatris supplies medicines to patients, hospitals, clinics, and pharmacies via wholesalers, distributors, institutional and specialty pharmacies, and e-commerce channels across the Americas, Europe, Asia, Africa, and the Middle East. Founded in 1961 and headquartered in Canonsburg, Pennsylvania, Viatris plays a significant role in global access to pharmaceuticals, including being a leading supplier of antiretroviral treatments in low- and lower-middle-income countries.
CEO Mr. Scott Andrew Smith Ph.D. · 30,000 employees · United States · https://www.viatris.com